Innovac Therapeutics develops vaccines and therapeutics using proprietary mRNA technology platforms and in‑house manufacturing capabilities. The company intends to use its recent financing to further develop its technology platform and manufacturing capability to advance lead programs to clinical stage. Innovac was founded in 2022 and is based in Boston, MA, with operations in Shanghai and Hangzhou, China. Leadership includes CEO Michael Zhang, Hang Yuan, PhD, and Nicholas Valiante. Upon closing the round Innovac also appointed David Bernstein, MD, Shan Lu, MD, PhD, and Elaine Mardis, PhD to its scientific advisory board. The company is positioning to move its lead programs into clinical development as it scales its platform and manufacturing.

Total raised

$18M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2023